ArticleEmerging microbes & infections2026
Community-based "X-ray+Xpert® MTB/RIF ultra pooling test" case-finding strategy among high-risk groups in rural areas: a prospective application study.
Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Active case-finding (ACF) strategies for tuberculosis (TB) in high-incidence rural areas require cost-effective solutions. We evaluated a novel community-based ACF strategy integrating pooled sputum molecular testing via Xpert® MTB/RIF Ultra. A prospective study was conducted in three high-TB-incidence rural townships in Zhejiang, China (2024). Residents aged ≥65 years underwent centralized health check-ups, including chest X-rays (CXR). Sputum samples from eight consecutive individuals with abnormal CXR findings were pooled for Xpert® MTB/RIF Ultra testing. Positive pools prompted individual retesting. Participants with positive individual test results were referred to designated hospitals for standardized treatment. Among 16,558 eligible residents, 6,960 (42.0%) participated. CXR abnormalities were detected in 1,912 participants (27.5%), with 1,883 providing sputum samples. Pooled testing identified 32 bacteriologically confirmed TB cases among 1,883 participants with CXR abnormalities, yielding a detection rate of 1.7%. The number needed to screen (NNS) to identify one case was 218, which was 177 fewer than that required by the chest X-ray-based alone active case finding strategy. Screening yields of newly detected TB through ACF was 0.460%. The innovative strategy reduced per-case screening costs to US$4.37 (vs. US$54.78 for individual testing) and per-confirmed-case cost to US$949.49. Integrating a pooled Xpert® MTB/RIF Ultra testing with routine health check-ups provides a high-yield, cost-effective ACF strategy for detecting active TB in high-risk elderly populations in rural settings. This approach addresses key barriers to scalable community-based screening.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.